Mavacoxib CAS 170569-88-7

What is Mavacoxib CAS 170569-88-7?

Mavacoxib CAS 170569-88-7, is a cyclooxygenase-2 (COX-2) selective inhibitor research compound developed as a veterinary anti-inflammatory agent for conditions such as degenerative joint disease in dogs. It is supplied as an off-white to pale beige crystalline solid and is used as a reference standard or intermediate in biochemical and pharmaceutical research, particularly in studies of inflammation and related pathways.

Specification

Feature

• COX –2 Selective Inhibition:Functions as a selective inhibitor of cyclooxygenase-2 (COX-2), making it valuable for inflammation and pain mechanism research.
• Veterinary Application Background: Originally developed as a long-acting anti-inflammatory agent for veterinary use (e.g., degenerative joint disease).
• Stable Crystalline Form:Provided as a well-defined solid, facilitating accurate dosing and reproducible research results.
• Reference Standard Utility:Suitable as a reference or calibration compound in analytical method development and pharmacological assays.

Application

• Inflammation Pathway Research:Used in studies probing cyclooxygenase-2 activity, prostaglandin pathways, and anti-inflammatory mechanisms.
• Pharmacological Profiling:Employed as a model compound in comparative efficacy and mechanism studies of NSAIDs and COX-2 inhibitors.
• Analytical Method Development:Utilized as a reference standard in chromatographic and spectrometric analyses in pharmaceutical research labs.
• Veterinary Drug Research: Applied in investigations related to veterinary anti-inflammatory drug development based on COX-2 selectivity.

Packaging

Mikem offers flexible packaging options, including 25 kg of fiber drums for liquid products and 15–25 kg PP/PE bags for powder products, all customizable to meet your specific needs.